Oncology News | pharmaphorum

News

Gilead taps Tentarix for cancer, inflammation projects

Gilead Sciences has put $66 million down to start a collaboration with San Diego start-up Tentarix Biotherapeutics to develop new therapeutics for cancer and inflammatory

News

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least

News

AI can be used to speed up radiotherapy planning, says NICE

Draft guidance from NICE has recommended that nine artificial intelligence technologies can be used by NHS England to help plan the treatment of those undergoing external

News

FDA clears J&J's 2-in-1 tablet for prostate cancer

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

News

Mirati CEO David Meek steps down after Krazati setback

Mirati Therapeutics chief executive David Meek has agreed to step down by mutual agreement with the company's board, to be replaced on a temporary basis by founder and for

Gilead taps Tentarix for cancer, inflammation projects

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

AI can be used to speed up radiotherapy planning, says NICE

FDA clears J&J's 2-in-1 tablet for prostate cancer

J&J bags first FDA approval for a GPRC5D drug

Mirati CEO David Meek steps down after Krazati setback

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks